What do you recommend regarding the timing for NGS-based genomic profiling? Do you believe it should be used early in the neoadjuvant setting or only in advanced, resistant, or metastatic disease? (Korean)

What do you recommend regarding the timing for NGS-based genomic profiling? Do you believe it should be used early in the neoadjuvant setting or only in advanced, resistant, or metastatic disease? (Korean)

What is your recommendation regarding the timing of use for NGS-based genomic profiling? Do you believe it should be used early in the neoadjuvant setting or only in advanced, resistant, or metastatic disease?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Seung Tae Kim, MD

Seung Tae Kim, MD

Division of Hematology Oncology
Department of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, Korea